Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indivior plc

http://indivior.com/

Latest From Indivior plc

Keeping Track: Entasis’ Antibiotic Xacduro, Two Opioid Misuse Therapies Clear US FDA; Pfizer’s Paxlovid Makes It Official

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

China Biotech Finance Watch: Luzhu Bags $43.5m In Hong Kong IPO

In the private market, eight Chinese biotechs raised a combined $116m in deals backed by venture capital and private equity firms over the past few weeks.

China Financing

Pfizer/Seagen Merger Seems Set To Clear As US FTC Sticks To Traditional Review

Pink Sheet infographic breaks down the big pharma deals and required divestitures over the past four years. Seagen reports that Pfizer's acquisition of the company is expected to close late this year or in early 2024.

M & A Deals

Moderna & Merck’s mRNA Cancer Vaccine Secures EMA PRIME Designation

A total of four investigational products targeting unmet medical needs have made it onto the European Medicines Agency’s priority medicines scheme so far this year.

Review Pathway Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Indivior Inc.
    • Indivior UK Limited
    • Reckitt Benckiser Pharmaceuticals Inc. (RBP)
UsernamePublicRestriction

Register